Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-74,200
Closed -$5.55M 6940
2022
Q4
$5.55M Buy
74,200
+72,600
+4,538% +$5.17M ﹤0.01% 2738
2022
Q3
$103K Buy
+1,600
New +$111K ﹤0.01% 5269
2021
Q4
Sell
-4,600
Closed -$340K 6779
2021
Q3
$340K Buy
+4,600
New +$345K ﹤0.01% 4940
2021
Q1
Sell
-30,500
Closed -$2.22M 6181
2020
Q4
$2.22M Buy
+30,500
New +$2.15M ﹤0.01% 3402
2017
Q1
Sell
-135,000
Closed -$5.42M 5126
2016
Q4
$5.42M Hold
135,000
﹤0.01% 2388
2016
Q3
$5.24M Hold
135,000
﹤0.01% 2215
2016
Q2
$4.67M Buy
+135,000
New +$4.67M ﹤0.01% 2340

Other funds holding HOLX

JP Morgan Chase's HOLX Position: Q1 2026 in Review

JP Morgan Chase increased its Hologic (HOLX) stake by 96% in Q1 2026, buying an estimated $122M and bringing the position to 3,301,493 shares worth $249M. The position accounts for 0.02% of the portfolio, ranked #606.

JP Morgan Chase first reported a position in HOLX in Q2 2013 and has held it in 52 quarters since. The position peaked at $271M in Q2 2023. 704 funds tracked by Wall St. Rank hold HOLX as of Q1 2026.

  • JP Morgan Chase held 3,301,493 shares of Hologic worth $249M as of Q1 2026.
  • JP Morgan Chase bought 1,618,203 Hologic shares in Q1 2026, an estimated $122M.
  • Hologic made up 0.02% of JP Morgan Chase's portfolio in Q1 2026, its #606 holding.
  • JP Morgan Chase first reported a position in Hologic in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Hologic position peaked at $271M in Q2 2023.
  • 704 funds tracked by Wall St. Rank held Hologic as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.